Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer.

NCT00074854 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00074854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00074854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer.
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2002
Completion date
March 31, 2005
Enrollment
87
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms